Results 241 to 250 of about 31,417,423 (292)
Physiologically Based Pharmacokinetic Model for Long-Circulating Inorganic Nanoparticles
Nano Letters, 2016 A physiologically based pharmacokinetic model was developed for accurately characterizing and predicting the in vivo fate of long-circulating inorganic nanoparticles (NPs).
Zhi Ping Xu, Xiaowen Liang
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pharmacokinetics and Physiologically-Based Pharmacokinetic Modeling of Nanoparticles
Journal of Nanoscience and Nanotechnology, 2010The worldwide commerce involving nanoparticles will soon reach $1 trillion and already we have more than 600 commercial products containing nanoparticles. Because nanoparticles are invisible and little is known about their toxicities, there has been concern about health effects in humans.
Raymond S H, Yang +3 more
openaire +2 more sources
Physiologically Based Pharmacokinetic Modeling of Nanoparticles
ACS Nano, 2010Rapid expansion of nanoparticle research demands new technologies that will enable better interpretation of experimental data and assistance in the rational design of future nanoparticles. The use of physiologically based pharmacokinetic (PBPK) models may serve as powerful tools to meet these needs.
Li, Mingguang +3 more
openaire +3 more sources
Physiologically-based pharmacokinetic simulation modelling
Advanced Drug Delivery Reviews, 2002Drug selection is now widely viewed as an important and relatively new, yet largely unsolved, bottleneck in the drug discovery and development process. In order to achieve an efficient selection process, high quality, rapid, predictive and correlative ADME models are required in order for them to be confidently used to support critical financial ...
George M, Grass, Patrick J, Sinko
openaire +2 more sources
Physiologically Based Pharmacokinetic/Toxicokinetic Modeling
2012Physiologically based pharmacokinetic (PBPK) models differ from conventional compartmental pharmacokinetic models in that they are based to a large extent on the actual physiology of the organism. The application of pharmacokinetics to toxicology or risk assessment requires that the toxic effects in a particular tissue are related in some way to the ...
Jerry L, Campbell +4 more
openaire +2 more sources
Definition and validation of a patient-individualized physiologically-based pharmacokinetic model [PDF]
Computers and Chemical Engineering, 2016 Pharmacokinetic modeling based on a mechanistic approach is a promising tool for drug concentration prediction in living beings. The development of a reduced physiologically-based pharmacokinetic model (PBPK model), is performed by lumping organs and ...
Mario Grassi +2 more
exaly +2 more sources
Physiologically Based Pharmacokinetic Modeling of Arsenic in the Mouse
Journal of Toxicology and Environmental Health, Part A, 2004A remarkable feature of the carcinogenicity of inorganic arsenic is that while human exposures to high concentrations of inorganic arsenic in drinking water are associated with increases in skin, lung, and bladder cancer, inorganic arsenic has not typically caused tumors in standard laboratory animal test protocols.
P Robinan, Gentry +5 more
openaire +2 more sources
A physiologically based model for tramadol pharmacokinetics in horses
Journal of Theoretical Biology, 2017This work proposes an application of a minimal complexity physiologically based pharmacokinetic model to predict tramadol concentration vs time profiles in horses. Tramadol is an opioid analgesic also used for veterinary treatments. Researchers and medical doctors can profit from the application of mathematical models as supporting tools to optimize ...
Abbiati, Roberto Andrea +4 more
openaire +4 more sources
Physiologically based pharmacokinetic model for topotecan in mice
Journal of Pharmacokinetics and Pharmacodynamics, 2010Topotecan is a chemotherapeutic agent of choice for the second-line treatment of recurrent ovarian cancer. In this article, we have developed a physiologically based pharmacokinetic model to characterize and predict topotecan concentrations in mouse plasma and tissues. Single intravenous (IV) doses (5, 10 and 30 mg/kg) of topotecan were administered to
Dhaval K, Shah, Joseph P, Balthasar
openaire +2 more sources
Physiologically-based pharmacokinetic model for 2,4-dinitrophenol
Journal of Pharmacokinetics and Pharmacodynamics, 2022New approaches in drug development are needed to address the growing epidemic of obesity as the prevalence of obesity increases worldwide. 2,4-Dinitrophenol (DNP) is an oxidative phosphorylation uncoupling agent that was widely used in the early 1930s for weight loss but was quickly banned by the FDA due to the severe toxicities associated with the ...
Lyndsey F. Meyer +2 more
openaire +2 more sources